Examining the impact of aspirin on patients with chronic kidney disease; a systematic review and meta-analysis
Abstract
Introduction: Chronic kidney disease (CKD) poses a significant global health burden, and the efficacy and safety of aspirin in CKD patients have yielded conflicting results. Thus, our study aims to investigate the impact of aspirin consumption on individuals with CKD. Materials and Methods: This comprehensive systematic review and meta-analysis involved searching PubMed, ProQuest, Web of Science, Cochrane, and Google Scholar databases without any time restrictions until December 22, 2023. Data analysis was conducted using STATA 14 software, with a significance level set at P<0.05. Results: Our analysis encompassed 12 studies involving a total of 92,271 participants. The findings revealed no meaningfully significant relationship between aspirin administration (≤200 mg) and renal failure in these patients (OR: 0.99, 95% CI: 0.86, 1.14). Similarly, the use of low-dose aspirin (≤100 mg) did not impact renal failure in CKD patients (OR: 0.97, 95% CI: 0.81, 1.15). The association between aspirin administration and renal failure in CKD patients aged 50-59 years (OR: 1.11, 95% CI: 0.91, 1.34) and 60-69 years (OR: 0.96, 95% CI: 0.80, 1.15) was not statistically significant. However, aspirin use in CKD patients aged 70-79 demonstrated a reduction in renal failure (OR: 0.34, 95% CI: 0.14, 0.82). Furthermore, there was no statistically significant association between aspirin administration and all-cause death in CKD patients (OR: 0.96, 95% CI: 0.81, 1.13). Conclusion: Our findings…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 92,271 participants or records.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.